Also Maraviroc and BMS-813160: BMS-813160 overv
Post# of 145345
![](/assets/46931549/no_avatar_available_thumb.jpg)
BMS-813160 overview:
BMS-813160 is under development for solid tumor, metastatic colorectal cancer, pancreatic cancer, pancreatic ductal adenocarcinoma, gastric cancer, renal cell carcinoma and hepatocellular carcinoma. It is administered orally as a capsule. The drug candidate is a dual CCR2/CCR5 antagonist.
_______
So our trial results will eventually also be compared to Maraviroc & Bristol Meyers Squibb
Let's get it Leronlimab!!
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)